Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes

Brain and Development

Volumn 38, Issue 1, 2016, Pages 40-46

  Shi, Xiu Yu ^a,b   Tomonoh, Yuko ^a   Wang, Wen Ze ^a,c   Ishii, Atsushi ^a   Higurashi, Norimichi ^a,d   Kurahashi, Hirokazu ^e   Kaneko, Sunao ^f   Hirose, Shinichi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Central Hospital of Aichi Welfare Center for Persons with Developmental Disabilities   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

Author keywords

Antiepileptic drug therapy; Dravet syndrome; Efficacy; Genetic tests

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; LEVETIRACETAM; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; POTASSIUM BROMIDE; SODIUM BROMIDE; SODIUM CHANNEL NAV1.1; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; BROMIDE; SCN1A PROTEIN, HUMAN;

ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHROMOSOME DELETION; CLONIC SEIZURE; DNA FLANKING REGION; DRUG EFFICACY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENOTYPE; HEALTH CARE SURVEY; HUMAN; INTRON; LOSS OF APPETITE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NONSENSE MUTATION; RETROSPECTIVE STUDY; RNA SPLICING; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TERTIARY CARE CENTER; TONIC CLONIC SEIZURE; TREATMENT DURATION; ADOLESCENT; ADULT; EPILEPSIES, MYOCLONIC; GENETICS; GENOTYPING TECHNIQUE; INFANT; MUTATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; BROMIDES; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSIES, MYOCLONIC; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INFANT; MALE; MUTATION; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936972457     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2015.06.008     Document Type: Article

References (16)

1. Yakoub M., Dulac O., Jambaque I., et al. Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev 1992, 14:299-303.
2. Hurst D.L. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 1990, 31:397-400.
3. Dravet C., Bureau M., Guerrini R., Giraud N., Roger J. Severe myoclonic epilepsy in infants. Epileptic syndromes in infancy, childhood and adolescence 1992, 75-88. John Libbey, London. J. Roger, C. Dravet, M. Bureau, F.E. Dreifuss, A. Perret, P. Wolf (Eds.).
4. Mullen S.A., Scheffer I.E. Translational research in epilepsy genetics: sodium channels in man to interneuronopathy in mouse. Arch Neurol 2009, 66:21-26.
5. Ceulemans B., Boel M., Claes L., et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004, 19:516-521.
6. Chiron C. Stiripentol. Expert Opin Investig Drugs 2005, 14:905-911.
7. Kassai B., Chiron C., Augier S., et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008, 49:343-348.
8. Ceulemans B., Boel M., Leyssens K., et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012, 53:1131-1139.
9. Fukuma G., Oguni H., Shirasaka Y., et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004, 45:140-148.
10. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001, 42:796-803.
11. Wang J.W., Kurahashi H., Ishii A., Kojima T., Ohfu M., Inoue T., et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 2008, 49:1528-1534.
12. Inoue Y., Ohtsuka Y., Oguni H., et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009, 50:2362-2368.
13. Tanabe T., Awaya Y., Matsuishi T., et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) - a nationwide questionnaire survey in Japan. Brain Dev 2008, 30:629-635.
14. Oguni H., Hayashi K., Oguni M., et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia 1994, 35:1140-1145.
15. Takayanagi M., Yamamoto K., Nakagawa H., et al. Two successful cases of bromide therapy for refractory symptomatic localization-related epilepsy. Brain Dev 2002, 24:194-196.
16. Striano P., Coppola A., Pezzella M., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007, 69:250-254.